Frequent coauthors
- WALLACE OWEN BRENDAN 210
- FRANK SCOTT ALAN 210
- HUMMEL CONRAD WILSON 180
- JONES SCOTT ALAN 180
- SHEPHERD Timothy Alan 165
- DALLY Robert Dean 150
- JONES Charles David 120
- LEWIS Geroge Sal 120
- Fahey Kennan Joseph 105
- Bryant Henry Uhlman 105
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.